BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28232158)

  • 1. Neoadjuvant therapy in microsatellite-stable colorectal carcinoma induces concomitant loss of MSH6 and Ki-67 expression.
    Kuan SF; Ren B; Brand R; Dudley B; Pai RK
    Hum Pathol; 2017 May; 63():33-39. PubMed ID: 28232158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma.
    Bao F; Panarelli NC; Rennert H; Sherr DL; Yantiss RK
    Am J Surg Pathol; 2010 Dec; 34(12):1798-804. PubMed ID: 21107085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogenous MSH6 loss is a result of microsatellite instability within MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas.
    Graham RP; Kerr SE; Butz ML; Thibodeau SN; Halling KC; Smyrk TC; Dina MA; Waugh VM; Rumilla KM
    Am J Surg Pathol; 2015 Oct; 39(10):1370-6. PubMed ID: 26099011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers.
    Lawes DA; Pearson T; Sengupta S; Boulos PB
    Br J Cancer; 2005 Aug; 93(4):472-7. PubMed ID: 16106253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency.
    Pearlman R; Markow M; Knight D; Chen W; Arnold CA; Pritchard CC; Hampel H; Frankel WL
    Mod Pathol; 2018 Dec; 31(12):1891-1900. PubMed ID: 29967423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
    Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
    Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative diagnosis of Lynch syndrome with DNA mismatch repair immunohistochemistry on a diagnostic biopsy.
    Warrier SK; Trainer AH; Lynch AC; Mitchell C; Hiscock R; Sawyer S; Boussioutas A; Heriot AG
    Dis Colon Rectum; 2011 Dec; 54(12):1480-7. PubMed ID: 22067175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.
    Plaschke J; Engel C; Krüger S; Holinski-Feder E; Pagenstecher C; Mangold E; Moeslein G; Schulmann K; Gebert J; von Knebel Doeberitz M; Rüschoff J; Loeffler M; Schackert HK
    J Clin Oncol; 2004 Nov; 22(22):4486-94. PubMed ID: 15483016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.
    Morak M; Käsbauer S; Kerscher M; Laner A; Nissen AM; Benet-Pagès A; Schackert HK; Keller G; Massdorf T; Holinski-Feder E
    Fam Cancer; 2017 Oct; 16(4):491-500. PubMed ID: 28528517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
    Rambau PF; Duggan MA; Ghatage P; Warfa K; Steed H; Perrier R; Kelemen LE; Köbel M
    Histopathology; 2016 Aug; 69(2):288-97. PubMed ID: 26799366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
    Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
    Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
    Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
    Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
    Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
    Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation].
    Czakó L; Tiszlavicz L; Takács R; Baradnay G; Lonovics J; Cserni G; Závodná K; Bartosova Z
    Orv Hetil; 2005 May; 146(20):1009-16. PubMed ID: 15945244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in the identification of MSH6-associated colorectal cancer: rectal location, less typical histology, and a subset with retained mismatch repair function.
    Klarskov L; Holck S; Bernstein I; Okkels H; Rambech E; Baldetorp B; Nilbert M
    Am J Surg Pathol; 2011 Sep; 35(9):1391-9. PubMed ID: 21836479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation.
    Gill S; Lindor NM; Burgart LJ; Smalley R; Leontovich O; French AJ; Goldberg RM; Sargent DJ; Jass JR; Hopper JL; Jenkins MA; Young J; Barker MA; Walsh MD; Ruszkiewicz AR; Thibodeau SN
    Clin Cancer Res; 2005 Sep; 11(18):6466-71. PubMed ID: 16166421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.
    Lu KH; Schorge JO; Rodabaugh KJ; Daniels MS; Sun CC; Soliman PT; White KG; Luthra R; Gershenson DM; Broaddus RR
    J Clin Oncol; 2007 Nov; 25(33):5158-64. PubMed ID: 17925543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation?
    Vilkin A; Halpern M; Morgenstern S; Brazovski E; Gingold-Belfer R; Boltin D; Purim O; Kundel Y; Welinsky S; Brenner B; Niv Y; Levi Z
    Hum Pathol; 2014 Oct; 45(10):2029-36. PubMed ID: 25150747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.